J Cardiovasc Electrophysiol

• 

  Publication Venue For

  • The role of posterior wall isolation in catheter ablation of persistent atrial fibrillation..  32:2567-2576. 2021
  • Can catheter ablation of atrial fibrillation reverse heart failure with preserved ejection fraction? 2021
  • Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States..  32:2199-2206. 2021
  • Behavior of AV synchrony pacing mode in a leadless pacemaker during variable AV conduction and arrhythmias..  32:1947-1957. 2021
  • Renal denervation for the treatment of ventricular arrhythmias: A systematic review and meta-analysis..  32:1430-1439. 2021
  • Leadless pacemaker implant with concomitant atrioventricular node ablation: Experience with the Micra transcatheter pacemaker..  32:832-841. 2021
  • Procedure characteristics and outcomes of atrial fibrillation ablation procedures using cryoballoon versus radiofrequency ablation: A report from the GWTG-AFIB registry..  32:248-259. 2021
  • Healthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation..  31:3166-3175. 2020
  • Patient-reported outcomes and subsequent management in atrial fibrillation clinical practice: Results from the Utah mEVAL AF program..  31:3187-3195. 2020
  • Collaborative care for the wearable cardioverter defibrillator patient: Getting the patient and medical team "vested and active"..  31:2509-2515. 2020
  • Ablation of persistent atrial fibrillation: Challenges and solutions..  31:1809-1821. 2020
  • Hands on: How to approach patients undergoing lead extraction..  31:1801-1808. 2020
  • Implantable cardioverter-defibrillator lead revision following left ventricular assist device implantation..  31:1509-1518. 2020
  • Performance of a novel active fixation quadripolar left ventricular lead for cardiac resynchronization therapy: Attain Stability Quad Clinical Study results..  31:1147-1154. 2020
  • When ablating over epicardial fat, consider the path of least resistance!.  31:1125-1127. 2020
  • Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation..  30:2968-2976. 2019
  • Non-invasively quantified changes in left ventricular activation predict outcomes in patients undergoing cardiac resynchronization therapy..  30:2475-2483. 2019
  • Physicians' perceptions of shared decision-making for implantable cardioverter-defibrillators: Results of a physician survey..  30:2420-2426. 2019
  • Chromosome 4q25 variants and biomarkers of myocardial fibrosis in patients with atrial fibrillation..  30:1904-1913. 2019
  • Epicardial ganglionated plexus ablation: Safety considerations beyond the atria..  30:2189-2190. 2019
  • Watchman implantation in a patient with left atrial appendage thrombus..  30:1694-1695. 2019
  • Low lead one ratio predicts clinical outcomes in left bundle branch block..  30:709-716. 2019
  • Leadless pacemaker implant in patients with pre-existing infections: Results from the Micra postapproval registry..  30:569-574. 2019
  • The paradox of innovation with leadless pacing..  29:1705-1706. 2018
  • Effectiveness of high rate and delayed detection ICD programming by race: A MADIT-RIT substudy..  29:1418-1424. 2018
  • Peeling back of left bundle branch refractoriness facilitates mapping of a hemodynamically unstable atrial flutter..  29:1319-1320. 2018
  • Predicting AF recurrence after catheter ablation: Is it time to use the force?.  29:272-273. 2018
  • Stellate ganglion blockade for the treatment of refractory ventricular arrhythmias: A systematic review and meta-analysis..  28:1460-1467. 2017
  • Do new tools help us identify substrate to target for ablation in ventricular tachycardia?.  28:1068-1069. 2017
  • Treating cardiac dysrhythmias by targeting the neck: Off target or on the right track?.  28:909-911. 2017
  • Autonomic Modulation for the Treatment of Ventricular Arrhythmias: Therapeutic Use of Percutaneous Stellate Ganglion Blocks..  28:446-449. 2017
  • Safety and Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients With Chronic Kidney Disease..  28:39-48. 2017
  • Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT..  28:94-102. 2017
  • Impedance Guided Radiofrequency Ablation for Atrial Fibrillation: Something Old Is New Again..  27:1399-1402. 2016
  • Intermittent Capture of the Left Bundle With Permanent His Bundle Pacing: Mechanistic Insights and Implications for an Emerging Field..  27:1344-1348. 2016
  • The Risk of Sudden Cardiac Death in Mitral Valve Prolapse: Are All Patients Created Equal?.  27:469-470. 2016
  • Transcatheter Leadless Pacemaker Implantation for Complete Heart Block Following CoreValve Transcatheter Aortic Valve Replacement..  27:125-126. 2016
  • Reduction in Inappropriate ICD Therapy in MADIT-RIT Patients Without History of Atrial Tachyarrhythmia..  26:879-884. 2015
  • Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial..  26:151-157. 2015
  • Optimal management of Riata leads with no known electrical abnormalities or externalization: a decision analysis..  26:184-191. 2015
  • Feasibility of near real-time lesion assessment during radiofrequency catheter ablation in humans using acoustic radiation force impulse imaging..  25:1275-1283. 2014
  • Stability of rotors and focal sources for human atrial fibrillation: focal impulse and rotor mapping (FIRM) of AF sources and fibrillatory conduction..  25:1284-1292. 2014
  • Cardiac implantable electronic device removal in patients with left ventricular assist device associated infections..  25:1199-1205. 2014
  • Cardiac resynchronization therapy in patients with renal dysfunction: keep calm and carry on..  25:1196-1198. 2014
  • Initial independent outcomes from focal impulse and rotor modulation ablation for atrial fibrillation: multicenter FIRM registry..  25:921-929. 2014
  • Outcomes of atrioesophageal fistula following catheter ablation of atrial fibrillation treated with surgical repair versus esophageal stenting..  25:579-584. 2014
  • "Typical" cavotricuspid isthmus-dependent atrial flutter without the cava..  25:103-104. 2014
  • More bad news for cardiac resynchronization therapy in atrial fibrillation patients: what to do?.  24:1123-1124. 2013
  • Left atrial remodeling: shape before size?.  24:760-761. 2013
  • Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure..  24:664-671. 2013
  • Disproportionate costs and charges for pediatric catheter ablation: supply and demand... or just supply?.  24:170-172. 2013
  • Electrophysiology in China: a special supplement. Introduction..  23 Suppl 1:S1. 2012
  • Do ICD lead recalls affect physician--or patient--behavior? If not, why not?.  23:866-868. 2012
  • Maximum voltage-guided catheter ablation of typical atrial flutter: making a good procedure even better?.  23:486-488. 2012
  • Use of ventricular synchronized triggered atrial pacing to facilitate hemodynamic support during mapping and catheter ablation of ventricular vachycardia..  22:1174-1178. 2011
  • Cerebral magnetic resonance findings in asymptomatic patients after atrial fibrillation catheter ablation: cause for alarm or further study?.  22:969-972. 2011
  • Pulmonary vein contraction before and after radiofrequency ablation for atrial fibrillation..  22:169-174. 2011
  • Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation..  21:849-852. 2010
  • The impact of new and emerging clinical data on treatment strategies for atrial fibrillation..  21:946-958. 2010
  • Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis..  21:791-798. 2010
  • Can we improve the identification of ventricular scar to guide substrate-based ventricular tachycardia ablation?.  21:685-687. 2010
  • Paroxysmal high-grade atrioventricular block and syncope in a previously healthy child: what is the mechanism?.  21:585-587. 2010
  • Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial..  21:545-550. 2010
  • Pearls for ablation in congenital heart disease..  21:223-230. 2010
  • Rationale and design for the Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation (DETERMINE) trial..  20:982-987. 2009
  • The variability of the electrical properties of the pulmonary veins..  20:1046-1047. 2009
  • Mode of induction of ventricular tachycardia and prognosis in patients with coronary disease: the Multicenter UnSustained Tachycardia Trial (MUSTT)..  20:850-855. 2009
  • Arrhythmias in children having a single left superior vena cava and minimal structural heart disease..  20:182-186. 2009
  • Reduced ejection fraction, sudden cardiac death, and heart failure death in the mode selection trial (MOST): implications for device selection in elderly patients with sinus node disease..  19:1160-1166. 2008
  • Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)..  19:1059-1065. 2008
  • Time dependence of arrhythmias in ICD patients..  19:790-793. 2008
  • Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial..  19:720-724. 2008
  • Cryoablation of accessory pathways: incremental insights on the way toward a therapeutic panacea?.  19:348-350. 2008
  • Ethnicity and arrhythmia susceptibility..  19:427-429. 2008
  • Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias..  19:172-177. 2008
  • Incidence and predictors of sudden cardiac death in patients with diastolic heart failure..  18:1231-1235. 2007
  • Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy..  18:833-838. 2007
  • Action potential and QT prolongation not sufficient to cause Torsade de Pointes: role of action potential triangulation..  18:204-205. 2007
  • Ebstein's anomaly of the tricuspid valve: a Wolf(f) in sheep's clothing..  17:1337-1339. 2006
  • Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators..  17:931-936. 2006
  • Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II. 2017